Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 37Sleep Initiation and Maintenance Disorders 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castrate-sensitive Prostate Cancer 1Low Risk Prostate Cancer 1Fatigue 1Depression 1Adenocarcinoma 1

Interventions

Specimen Handling 5Magnetic Resonance Spectroscopy 5Cisplatin 4trastuzumab deruxtecan 3Platinum 3Docetaxel 3Carboplatin 3Biopsy 3pembrolizumab 2entrectinib 2darolutamide 2Trastuzumab 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Goserelin 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1sacituzumab govitecan 1pyrotinib 1pertuzumab 1luprolide acetate gel depot 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1camrelizumab 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × apalutamide × 90 days × Clear all
NCT04325828 2026-05-08

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡